Market Overview

UPDATE: JP Morgan Initiates Infinity Pharmaceuticals at Overweight on Positive Data

Share:
Related INFI
Mid-Day Market Update: TETRA Technologies Drops Following Weak Results; Krispy Kreme Shares Spike Higher
Mid-Day Market Update: U.S. Stocks Rise; Cree Shares Decline On Weak Outlook

JP Morgan initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $42.00 price target.

JP Morgan commented, "We are initiating coverage of Infinity Pharmaceuticals with an Overweight rating based on the potential of IPI-145, the company's wholly owned, possibly best-in-class oral drug candidate for the treatment of hematologic (blood) cancers, which we believe is a billion-dollar-plus opportunity. In our view, 2013 is shaping up as another event-driven year for INFI. The stock has had an impressive run, we believe based on promising early data and recent market precedent (set by PCYC in particular)."

Infinity Pharmaceuticals closed at $33.37 on Wednesday.

Latest Ratings for INFI

DateFirmActionFromTo
Mar 2016WedbushDowngradesNeutralUnderperform
Mar 2016JMP SecuritiesMaintainsMarket Outperform
Mar 2016FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Analyst Ratings

 

Related Articles (INFI)

View Comments and Join the Discussion!